If you are an external healthcare provider and do not have access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Requisition Form is required. If you are an internal healthcare provider with access to Nationwide Children’s Epic system, no requisition form is required; Instead, please place the lab order electronically in Epic.

Acceptable specimen types for this test include fresh tissue, snap-frozen tissue, OCT-embedded tissue, formalin-fixed paraffin-embedded (FFPE) tissue, and unstained slides (6 consecutive, unstained, 3 micron-thick sections placed on positively charged slides must accompany a hematoxylin and eosin (H&E) stained slide from the adjacent section); decalcified sections will not be accepted. All specimens must be labeled with a patient name and at least one additional identifier (DOB, MRN, Specimen ID#, etc.). Sample submission prior to receiving therapy is strongly preferred. Please note, tissue blocks will be returned after testing is complete if there is remaining sample. If completing a test requisition, include return shipping information in the space provided.

All submitted specimens must be accompanied by a pathology report; samples must contain a minimum of ≥10% tumor. A pathology quality control assessment will be carried out by a Nationwide Children's Laboratory Services pathologist for all tumor submitted samples to verify the presence of adequate tumor in the submitted tissue.

Please send all samples via overnight courier service. Snap-frozen or OCT-embedded tissue should be sent covered in dry ice. Fresh tissue, FFPE tissue block (s), or FFPE slides may be sent at room temperature. Saturday deliveries are accepted; (please check "Saturday Delivery" on shipment label for Saturday delivery). Please call (614) 722-5321 for any questions regarding this test.

Ewing sarcoma (ES) is an aggressive, malignant tumor that affects bone and soft tissue in children and young adults. ES is commonly caused by a chromosomal translocation resulting in an oncogenic gene fusion protein (PMID: 33497548). The presence or absence of a gene rearrangement involving EWSR1 can aid in differentiating sarcoma subtypes (e.g. rare soft tissue vs clear cell sarcoma). Two chromosomal translocations are observed in the majority of Ewing sarcomas: t(11;22)(q24;q12) resulting in EWSR1::FLI1 gene fusion, present in 85% of ES, and t(21;22)(q21;q12) resulting in EWSR1::ERG gene fusion, present in 10% of ES. This fluorescence in situ hybridization (FISH) analysis using the EWSR1 breakapart probe design will determine if the EWSR1 gene is rearranged but will not identify the EWSR1 gene fusion partner. Early detection of EWSR1 gene rearrangements is critical for diagnosis, targeted neoadjuvant therapy, and long-term survival (PMID: 33919988).         

If you are an external healthcare provider and do not have access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Requisition Form is required. If you are an internal healthcare provider with access to Nationwide Children’s Epic system, no requisition form is required; Instead, please place the lab order electronically in Epic.

Acceptable specimen types for this test include fresh tissue, snap-frozen tissue, OCT-embedded tissue, formalin-fixed paraffin-embedded (FFPE) tissue, and unstained slides (6 consecutive, unstained, 3 micron-thick sections placed on positively charged slides must accompany a hematoxylin and eosin (H&E) stained slide from the adjacent section); decalcified sections will not be accepted. All specimens must be labeled with a patient name and at least one additional identifier (DOB, MRN, Specimen ID#, etc.). Sample submission prior to receiving therapy is strongly preferred. Please note, tissue blocks will be returned after testing is complete if there is remaining sample. If completing a test requisition, include return shipping information in the space provided.

All submitted specimens must be accompanied by a pathology report; samples must contain a minimum of ≥10% tumor. A pathology quality control assessment will be carried out by a Nationwide Children's Laboratory Services pathologist for all tumor submitted samples to verify the presence of adequate tumor in the submitted tissue.

Please send all samples via overnight courier service. Snap-frozen or OCT-embedded tissue should be sent covered in dry ice. Fresh tissue, FFPE tissue block (s), or FFPE slides may be sent at room temperature. Saturday deliveries are accepted; (please check "Saturday Delivery" on shipment label for Saturday delivery). Please call (614) 722-5321 for any questions regarding this test.

Ewing sarcoma (ES) is an aggressive, malignant tumor that affects bone and soft tissue in children and young adults. ES is commonly caused by a chromosomal translocation resulting in an oncogenic gene fusion protein (PMID: 33497548). The presence or absence of a gene rearrangement involving EWSR1 can aid in differentiating sarcoma subtypes (e.g. rare soft tissue vs clear cell sarcoma). Two chromosomal translocations are observed in the majority of Ewing sarcomas: t(11;22)(q24;q12) resulting in EWSR1::FLI1 gene fusion, present in 85% of ES, and t(21;22)(q21;q12) resulting in EWSR1::ERG gene fusion, present in 10% of ES. This fluorescence in situ hybridization (FISH) analysis using the EWSR1 breakapart probe design will determine if the EWSR1 gene is rearranged but will not identify the EWSR1 gene fusion partner. Early detection of EWSR1 gene rearrangements is critical for diagnosis, targeted neoadjuvant therapy, and long-term survival (PMID: 33919988).         

Ewing sarcoma (ES) is an aggressive, malignant tumor that affects bone and soft tissue in children and young adults. ES is commonly caused by a chromosomal translocation resulting in an oncogenic gene fusion protein (PMID: 33497548). The presence or absence of a gene rearrangement involving EWSR1 can aid in differentiating sarcoma subtypes (e.g. rare soft tissue vs clear cell sarcoma). Two chromosomal translocations are observed in the majority of Ewing sarcomas: t(11;22)(q24;q12) resulting in EWSR1::FLI1 gene fusion, present in 85% of ES, and t(21;22)(q21;q12) resulting in EWSR1::ERG gene fusion, present in 10% of ES. This fluorescence in situ hybridization (FISH) analysis using the EWSR1 breakapart probe design will determine if the EWSR1 gene is rearranged but will not identify the EWSR1 gene fusion partner. Early detection of EWSR1 gene rearrangements is critical for diagnosis, targeted neoadjuvant therapy, and long-term survival (PMID: 33919988).         

If you are an external healthcare provider and do not have access to Nationwide Children’s Epic system, submission of a completed Oncology Genetic Requisition Form is required. If you are an internal healthcare provider with access to Nationwide Children’s Epic system, no requisition form is required; Instead, please place the lab order electronically in Epic.

Acceptable specimen types for this test include fresh tissue, snap-frozen tissue, OCT-embedded tissue, formalin-fixed paraffin-embedded (FFPE) tissue, and unstained slides (6 consecutive, unstained, 3 micron-thick sections placed on positively charged slides must accompany a hematoxylin and eosin (H&E) stained slide from the adjacent section); decalcified sections will not be accepted. All specimens must be labeled with a patient name and at least one additional identifier (DOB, MRN, Specimen ID#, etc.). Sample submission prior to receiving therapy is strongly preferred. Please note, tissue blocks will be returned after testing is complete if there is remaining sample. If completing a test requisition, include return shipping information in the space provided.

All submitted specimens must be accompanied by a pathology report; samples must contain a minimum of ≥10% tumor. A pathology quality control assessment will be carried out by a Nationwide Children's Laboratory Services pathologist for all tumor submitted samples to verify the presence of adequate tumor in the submitted tissue.

Please send all samples via overnight courier service. Snap-frozen or OCT-embedded tissue should be sent covered in dry ice. Fresh tissue, FFPE tissue block (s), or FFPE slides may be sent at room temperature. Saturday deliveries are accepted; (please check "Saturday Delivery" on shipment label for Saturday delivery). Please call (614) 722-5321 for any questions regarding this test.

Ewing sarcoma (ES) is an aggressive, malignant tumor that affects bone and soft tissue in children and young adults. ES is commonly caused by a chromosomal translocation resulting in an oncogenic gene fusion protein (PMID: 33497548). The presence or absence of a gene rearrangement involving EWSR1 can aid in differentiating sarcoma subtypes (e.g. rare soft tissue vs clear cell sarcoma). Two chromosomal translocations are observed in the majority of Ewing sarcomas: t(11;22)(q24;q12) resulting in EWSR1::FLI1 gene fusion, present in 85% of ES, and t(21;22)(q21;q12) resulting in EWSR1::ERG gene fusion, present in 10% of ES. This fluorescence in situ hybridization (FISH) analysis using the EWSR1 breakapart probe design will determine if the EWSR1 gene is rearranged but will not identify the EWSR1 gene fusion partner. Early detection of EWSR1 gene rearrangements is critical for diagnosis, targeted neoadjuvant therapy, and long-term survival (PMID: 33919988).